

| | |
|-------------------------|---|
| Reference: | FOI.2063.19 |
| Subject: | In-patient vitamin K antagonists (VKA) dosing/VTE risk assessment practices |
| Date of Request: | 28 November 2019 |

Requested:

1. Does your Trust have an Anticoagulant Service for:
 - a. In-patients and out-patients YES/NO
 - b. In-patients only YES/NO
 - c. Outpatient only YES/NO

2. How many inpatient beds does your Trust have (at each site if more than 1 site)?
 - a. How many sites do you inpatient dose (if applicable)?

3. Who doses VKA for your inpatient population?
 - a. Doctors
 - b. Advanced nurse practitioners
 - c. Biomedical Scientists
 - d. Clinical Nurse Specialists – if so are they nurse prescribers?
 - e. Pharmacists - If so are they prescribers?
 - f. Other – Please specify

4. How many individuals who are not doctors perform this role in the groups specified above?

5. If you dose warfarin for out-patients, how many warfarin patients do you currently dose?
 - a. Which dosing software do you use?

6. Does your Trust run nurse led Anticoagulation clinics? Yes/NO

7. If there are no nurse led clinics, who is responsible for management of patients taking VKA within your trust?

8. Who completes your VTE Risk assessments?
 - a. Ward Doctors
 - b. Nurses
 - c. Pharmacists
 - d. ANPs
 - e. Other – Please specify

9. What is your current VTE Risk assessment compliance rate?

Response:

1. Hywel Dda University Health Board (UHB) confirms answer 1c, outpatient anticoagulant service only.

2. This information is already within the public domain therefore the UHB has applied an exemption under Section 21 of the Freedom of Information Act 2000 (the Act) as the information is accessible by another means. The number of inpatient beds is available on the Welsh Government website for the periods 2009/10 to 2018/19.

For ease of reference please click on the attached link which will take you directly to the statistics for Wales webpage: <https://statswales.gov.wales/Catalogue/Health-and-Social-Care/NHS-Hospital-Activity/NHS-Beds/nhsbeds-by-organisation-site>

The 2019/20 data is not currently available. However, is intended for future publication and is therefore exempt under Section 22 of the Act. Section 22 can be applied when there is a clear intention to publish the information requested at the time the request was received.

- 2a. The UHB confirms there are no sites that inpatient dose.
3. The UHB confirms answer 3a, doctors dose Vitamin K Antagonists (VKA) for the inpatient population.
4. The UHB confirms only doctors perform VKA dosing.
5. The UHB confirms within the table below, the current number of out-patients dosed with Warfarin for each hospital:

| Hospital | Patients |
|----------------------------------|----------|
| Bronglais General Hospital(BGH) | 300 |
| Glangwili General Hospital (GGH) | 1,216 |
| Prince Philip Hospital (PPH) | 1,386 |
| Withybush General Hospital (WGH) | 1,308 |

- 5a. The UHB uses DAWN anticoagulant software.
6. The UHB does not provide nurse led anticoagulation clinics.
7. The UHB's medical staff manage the administering of VKA for in-patients.
8. The UHB's medical staff complete the Venous Thromboembolism (VTE) risk assessments.
9. The UHB is unable to provide the current VTE risk assessment compliance rate as the information is not held. However the UHB confirms it is implementing measures to introduce a Thromboprophylaxis Policy which will include a new format of risk assessment recording based on the department of health and social care documents used across Wales. The UHB provides below, an all Wales medication chart with figures collected by the pharmacy department:

